Avant Technologies, Inc.

2025-01-28 02:23:16

(MENAFN- Baystreet) 12:49 PM EST - Avant Technologies, Inc. : With its partner, Ainnova Tech, Inc., a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that Avant has started the budgeting process to fund Ainnova's upcoming interactions with the U.S. Food and Drug Administration (FDA). Ainnova will begin by requesting a pre-submission meeting with the FDA for guidance on the clinical testing needed for its Vision AI platform in the early detection of diabetic retinopathy, which will culminate with an FDA 510(k) submission to obtain clearance from the FDA to market its technology. Avant Technologies, Inc. shares O are trading off 3 cents at $0.67.

Full Press Release:

MENAFN28012025000212011056ID1109136487

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.